{
    "Trade/Device Name(s)": [
        "IMMULITE/IMMULITE 1000 OM-MA",
        "IMMULITE 2000 OM-MA"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products Ltd",
    "510(k) Number": "K213510",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981297",
        "K983391"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK"
    ],
    "Summary Letter Date": "February 24, 2023",
    "Summary Letter Received Date": "February 27, 2023",
    "Submission Date": "May 11, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA125 antigen",
        "Cancer Antigen 125"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "IMMULITE analyzer",
        "IMMULITE 1000 analyzer",
        "IMMULITE 2000 analyzer",
        "IMMULITE 2000 XPi analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Immunometric assay"
    ],
    "Methodologies": [
        "Immunologic sandwich",
        "Chemiluminescent detection",
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens IMMULITE/IMMULITE 1000 OM-MA and IMMULITE 2000 OM-MA assays for quantitative measurement of CA125 antigen in serum using chemiluminescent immunoassay.",
    "Indications for Use Summary": "For in vitro quantitative measurement of CA125 antigen in serum as an aid in monitoring therapy response and detecting residual ovarian cancer in patients post first-line therapy, intended for use with IMMULITE, IMMULITE 1000, and IMMULITE 2000 analyzers.",
    "fda_folder": "Immunology"
}